CXCL-13 Regulates Resistance to 5-Fluorouracil in Colorectal Cancer
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose 5-Fluorouracil (5-Fu) is used as a conventional chemotherapy drug in chemotherapy for patients with advanced colorectal cancer, but many patients still suffer from treatment failure due to 5-Fu resistance. Emerging observations revealed the important role of chemokine (C-X-C motif) ligand 13 (CXCL-13) in tumor microenvironment and its relationship with prognosis in patients with colorectal cancer. This study is designed to reveal the important role of CXCL-13 in causing colorectal cancer resistance to 5-Fu. Materials and Methods CXCL-13 levels of patient's serum or cell culture supernatants were measured separately by enzyme-linked immunosorbent assay. In cell assays, cell viability is detected by Cell Counting Kit-8. Therefore, the recombinant human CXCL-13 was used to simulate its high expression in cells while its antibody and siRNA were used to reduce CXCL-13 expression in cells. Results In this study, we demonstrated that CXCL-13 is associated with 5-Fu resistance by culture medium exchange experiments and cytokine arrays of colorectal cancer resistant and nonresistant cells. Clinical studies showed that CXCL-13 is highly expressed in the serum of 5-Fu–resistant patients. High levels of serum CXCL-13 also predict a worse clinical outcome. The addition of recombinant CXCL-13 cytokine resulted in 5-Fu resistance, while its antibody overcame 5-Fu resistance, and knockdown of CXCL-13 expression by siRNA also reduced 5-Fu resistance, which can be saved by added recombination CXCL-13. Conclusion These results not only identify a CXCL-13 mediated 5-Fu resistance mechanism but also provide a novel target for 5-Fu–resistant colorectal cancer in prevention and treatment strategies.
Abstract
Purpose 5-Fluorouracil (5-Fu) is used as a conventional chemotherapy drug in chemotherapy for patients with advanced colorectal cancer, but many patients still suffer from treatment failure due to 5-Fu resistance. Emerging observations revealed the important role of chemokine (C-X-C motif) ligand 13 (CXCL-13) in tumor microenvironment and its relationship with prognosis in patients with colorectal cancer. This study is designed to reveal the important role of CXCL-13 in causing colorectal cancer resistance to 5-Fu. Materials and Methods CXCL-13 levels of patient's serum or cell culture supernatants were measured separately by enzyme-linked immunosorbent assay. In cell assays, cell viability is detected by Cell Counting Kit-8. Therefore, the recombinant human CXCL-13 was used to simulate its high expression in cells while its antibody and siRNA were used to reduce CXCL-13 expression in cells. Results In this study, we demonstrated that CXCL-13 is associated with 5-Fu resistance by culture medium exchange experiments and cytokine arrays of colorectal cancer resistant and nonresistant cells. Clinical studies showed that CXCL-13 is highly expressed in the serum of 5-Fu–resistant patients. High levels of serum CXCL-13 also predict a worse clinical outcome. The addition of recombinant CXCL-13 cytokine resulted in 5-Fu resistance, while its antibody overcame 5-Fu resistance, and knockdown of CXCL-13 expression by siRNA also reduced 5-Fu resistance, which can be saved by added recombination CXCL-13. Conclusion These results not only identify a CXCL-13 mediated 5-Fu resistance mechanism but also provide a novel target for 5-Fu–resistant colorectal cancer in prevention and treatment strategies.
참고문헌 (30)
- Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 68, pp.394~424 (2018)
- Center MM, "Worldwide variations in colorectal cancer", CA Cancer J Clin, 59, pp.366~378 (2009)
- Saltz LB, "Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group", N Engl J Med, 343, pp.905~914 (2000)
- Panczyk M, "Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years", World J Gastroenterol, 20, pp.9775~9827 (2014)
- Wu Q, "Multi-drug resistance in cancer chemotherapeutics : mechanisms and lab approaches", Cancer Lett, 347, pp.159~166 (2014)
- Iyer AK, "Role of integrated cancer nanomedicine in overcoming drug resistance", Adv Drug Deliv Rev, 65, pp.1784~1802 (2013)
- Xie T, "MicroRNAs as regulators, biomarkers and therapeutic targets in the drug resistance of colorectal cancer", Cell Physiol Biochem, 40, pp.62~76 (2016)
- Shen Y, "Epigenomics alternations and dynamic transcriptional changes in responses to 5-fluorouracil stimulation reveal mechanisms of acquired drug resistance of colorectal cancer cells", Pharmacogenomics J, 18, pp.23~28 (2018)
- Jones VS, "Cytokines in cancer drug resistance : cues to new therapeutic strategies", Biochim Biophys Acta, 1865, pp.255~265 (2016)
- Zahreddine H, "Mechanisms and insights into drug resistance in cancer", Front Pharmacol, 4, pp.28~ (2013)
- Chow MT, "Chemokines in cancer", Cancer Immunol Res, 2, pp.1125~1131 (2014)
- Balkwill F, "Cancer and the chemokine network", Nat Rev Cancer, 4, pp.540~550 (2004)
- Huber AK, "Targeting CXCL13 during neuroinflammation", Adv Neuroimmune Biol, 6, pp.1~8 (2015)
- Gu-Trantien C, "CD4(+)follicular helper T cell infiltration predicts breast cancer survival", J Clin Invest, 123, pp.2873~2892 (2013)
- Chen L, "The expression of CXCL13 and its relation to unfavorable clinical characteristics in young breast cancer", J Transl Med, 13, pp.168~ (2015)
- Gu-Trantien C, "CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer", JCI Insight, 2, pp.91487~ (2017)
- Fan L, "CXCL13 is androgen-responsive and involved in androgen induced prostate cancer cell migration and invasion", Oncotarget, 8, pp.53244~53261 (2017)
- Lazennec G, "Chemokines and chemokine receptors : new insights into cancer-related inflammation", Trends Mol Med, 16, pp.133~144 (2010)
- Bindea G, "Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer", Immunity, 39, pp.782~795 (2013)
- Agesen TH, "ColoGuideEx : a robust gene classifier specific for stage II colorectal cancer prognosis", Gut, 61, pp.1560~1567 (2012)
- Olsen RS, "Circulating inflammatory factors associated with worse longterm prognosis in colorectal cancer", World J Gastroenterol, 23, pp.6212~6219 (2017)
- Murakami Y, "Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells", Int J Oncol, 17, pp.277~283 (2000)
- Butera G, "Autocrine mechanisms of cancer chemoresistance", Semin Cell Dev Biol, 78, pp.3~12 (2018)
- Singh A, "EMT, cancer stem cells and drug resistance : an emerging axis of evil in the war on cancer", Oncogene, 29, pp.4741~4751 (2010)
- Miller MA, "Molecular pathways : receptor ectodomain shedding in treatment, resistance, and monitoring of cancer", Clin Cancer Res, 23, pp.623~629 (2017)
- Zhou W, "Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance", Oncogene, 37, pp.3981~3997 (2018)
- Qi XW, "Expression features of CXCR5 and its ligand, CXCL13 associated with poor prognosis of advanced colorectal cancer", Eur Rev Med Pharmacol Sci, 18, pp.1916~1924 (2014)
- Lillard J, "CXCL13 inhibition prevents bone metastasis in hormone-refractory prostate cancer (133.8)", J Immunol, 184, pp.133.8~ (2010)
- Zhu Z, "CXCL13-CXCR5axis promotes the growth and invasion of colon cancer cells via PI3K", AKT pathway, 2015, pp.400, 287~295
- Waldner MJ, "779 CXCL13-CXCR5 signaling is required for the anti-tumor immune response in colorectal cancer", Gastroenterology, 146, pp.S131~ (2014)